APL and Supportive Care Flashcards

1
Q

APL

A

Acute Promyelocytic Leukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

APL arises from

A

single translocation like CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

pathogenesis APL

A

oncologic emergency secondary to rapidly evolving clotting abnormalities and risk for fatal hemorrhage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

treatment of APL

A

All-trans retinoic acid

Arsenic tri-oxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

mechanism ATRA for APL

A

directly addresses maturation block

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

mechanism arsenic tri-oxide for APL

A

Induces degradation of chimeric protein

Induces apoptosis at higher doses by uncertain (and possibly multiple) mechanisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

3 kinds of nausea

A

Anticipatory
Acute
Delayed (>24 hrs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

2 pathways for nausea-vomiting

A

peripheral pathway - GI tract release 5HT onto vagal afferent (acute phase)

central pathway - (chronic, delayed) area postrema to vagus nerve w/ substance P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what cancers known for thrombotic diathesis

A

Pancreas, Breast, Prostate, Bladder, Lung and CNS cancers all well known for thrombotic diathesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what clotting markers are consistently correlated w/ poor survival

A

Elevated D-dimer, elevated INR, and other measures of hypercoagulability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

most active agent for management of DVT in cancer

A

Low-molecular weight heparin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

clots and therapeutic warfarin

A

Clots often continue to form in setting of “therapeutic” warfarin
(distinctly inferior way – need LMWH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

tx management of dvt in cancer

A

Cancer patients should get at least 2 weeks of LMWH, and ideally stay on LMWH until thrombogenic stimulus (e.g. chemotherapy) is removed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

which cancers almost universally affect bone

A

breast and prostate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

bone directed treatment extends survival in what cancers

A

Myeloma and Breast and Renal Cell (NOT in Prostate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

classic agents for anti-resorptive therapy of bone

A

bisphosphonate

17
Q

most potent and most used anti-resorptive therapy of bone at present

A

zoledronic acid

18
Q

treatment of constipation: gentle and does not generate gas

A

polyethylene glycol (miralax)

19
Q

______ to prevent tearing (with constipation) is quite important

A

mineral oil

20
Q

need to replace ____ w/ diarrhea

A

electrolyte

21
Q

what do you need to remember with both diarrhea and constipation

A

fiber

22
Q

what is extremely useful in tx of diarrhea

A

tincture of opium

23
Q

what are useful for quite useful for secretory diarrhea unresponsive to other measures

A

somatostatin analogues

24
Q

myelosuppression tx: now available as a recombinant therapeutic peptide

A

Granulocyte Colony Stimulating Factor (G-CSF)

25
Q

SE G-SCF

A

In young people getting only moderately myelosuppressive therapy, the long-acting form causes BAD low back pain. Snee this in the ED.

26
Q

anemia tx: now available as a recombinant therapeutic peptide

A

Epo

27
Q

therapeutic outcome with Epo

A

Unfortunately, pushing Hgb above 10 is consistently associated with WORSE outcome
BAD

28
Q

Use of EPO restricted to

A

The use of EPO for cancer patients is pretty much restricted to transfusion-dependent marrow failure

29
Q

Two agents FDA approved for refractory ITP

A

eltrombopag
romiplostim

No routine use of these agents at the moment for chemo-induced thrombocytopenia